BOLD - Audentes Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BOLD is currently covered by 3 analysts with an average price target of $42.85. This is a potential upside of $41.75 (3795.45%) from yesterday's end of day stock price of $1.1.

Audentes Therapeutics's activity chart (see below) currently has 62 price targets and 19 ratings on display. The stock rating distribution of BOLD is 16.67% HOLD and 83.33% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 7.69% with an average time for these price targets to be met of 12.46 days.

Highest price target for BOLD is $4, Lowest price target is $3, average price target is $3.5.

Most recent stock forecast was given by MITCHELL KAPOOR from HC WAINWRIGHT on 11-Aug-2025.

Currently out of the existing stock ratings of BOLD, 1 are a HOLD (16.67%), 5 are a BUY (83.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 02-Jun-2025

$4

$2.89 (260.36%)

$5

7 months 21 days ago
(11-Aug-2025)

0/2 (0%)

$2.89 (260.36%)

Hold Since 28-May-2025

$3

$1.89 (170.27%)

$25

10 months 4 days ago
(28-May-2025)

0/2 (0%)

$1.8 (150.00%)

Hold Since 04-Dec-2019

$60

$58.89 (5305.41%)

$48

6 years 3 months 28 days ago
(04-Dec-2019)

0/4 (0%)

$60 (0.00%)

Hold Since 03-Dec-2019

$60

$58.89 (5305.41%)

$55

6 years 3 months 29 days ago
(03-Dec-2019)

0/10 (0%)

$60 (0.00%)

Hold Since 03-Dec-2019

$60

$58.89 (5305.41%)

$21

6 years 3 months 29 days ago
(03-Dec-2019)

0/3 (0%)

$60 (0.00%)

Show more analysts

Please expand the browser size to see the chart

What is BOLD (Audentes Therapeutics) average time for price targets to be met?

On average it took 12.46 days on average for the stock forecasts to be realized with a an average price target met ratio 7.69

Which analyst has the current highest performing score on BOLD (Audentes Therapeutics) with a proven track record?

JOSH SCHIMMER

Which analyst has the most public recommendations on BOLD (Audentes Therapeutics)?

Josh Schimmer works at CANTOR FITZGERALD and has 3 price targets and 3 ratings on BOLD

Which analyst is the currently most bullish on BOLD (Audentes Therapeutics)?

Mohit Bansal with highest potential upside - $58.89

Which analyst is the currently most reserved on BOLD (Audentes Therapeutics)?

Joshua Schimmer with lowest potential downside - -$19.97

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?